Intradermal and virosomal influenza vaccines for preventing influenza hospitalization in the elderly during the 2011-2012 influenza season: A comparative effectiveness study using the Valencia health care information system

Vaccine

Volumn 32, Issue 42, 2014, Pages 5447-5454

  Puig Barbera J ^a   Natividad Sancho, A ^a   Calabuig Perez J ^b   Lluch Rodrigo, J A ^c   Pastor Villalba, E ^c   Martinez Ubeda S ^a   Diez Domingo J ^a  

^a Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la Comunitat Valenciana   (Spain)

^b Servicio de Análisis de Sistemas de Información Sanitaria Conselleria de Sanitat   (Spain)

^c Servicio de Salud Infantil Y de la Mujer   (Spain)

Author keywords

Aged; Cohort studies; Comparative effectiveness research; Hospitalization; Influenza vaccines

Indexed keywords

INFLUENZA VACCINE; INTRADERMAL TRIVALENT INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; VIROSOMAL TRIVALENT INFLUENZA VACCINE; VIROSOME VACCINE;

AGE; AGED; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONFIDENCE INTERVAL; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; FEMALE; GERIATRIC PATIENT; HAZARD RATIO; HEALTH CARE SYSTEM; HEALTH INSURANCE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MICRONEEDLE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SEASONAL INFLUENZA; SEX; SPAIN; VERY ELDERLY; CLASSIFICATION; COMPARATIVE STUDY; INFLUENZA, HUMAN; STATISTICS AND NUMERICAL DATA;

AGED; AGED, 80 AND OVER; FEMALE; HOSPITALIZATION; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SPAIN; VACCINES, VIROSOME;

EID: 84922400095     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.095     Document Type: Article

References (36)

1. Barker W.H., Mullooly J.P. Influenza vaccination of elderly persons. Reduction in pneumonia and influenza hospitalizations and deaths. J Am Med Assoc 1980, 244:2547-2549.
2. Barker W.H. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970-78. Am J Public Health 1986, 76:761-765.
3. Mullooly J.P., Bennett M.D., Hornbrook M.C., Barker W.H., Williams W.W., Patriarca P.A., et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994, 121:947-952.
4. Fleming D., Harcourt S., Smith G. Influenza and adult hospital admissions for respiratory conditions in England 1989-2001. Commun Dis Public Health 2003, 6:231-237.
5. Wong C.M., Chan K.P., Hedley A.J., Peiris J.S. Influenza-associated mortality in Hong Kong. Clin Infect Dis 2004, 39:1611-1617.
6. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. J Am Med Assoc 2003, 289:179-186.
7. Osterholm M.T., Kelley N.S., Sommer A., Belongia E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2011, 12:36-44.
8. Gavazzi G., Krause K.H. Ageing and infection. Lancet Infect Dis 2002, 2:659-666.
9. Glück R., Mischler R., Finkel B., Que J.U., Scarpa B., Cryz S.J. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994, 344:160-163.
10. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001, 19:2673-2680.
11. Nicolas J.F., Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008, 7:1201-1214.
12. Falsey A.R., Treanor J.J., Tornieporth N., Capellan J., Gorse G.J. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009, 200:172-180.
13. DiazGranados C.A., Dunning A.J., Jordanov E., Landolfi V., Denis M., Talbot H.K. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine 2013, 31:861-866.
14. Portero-Alonso A., Pastor-Villalba E., Martín-Ivorra R., Alguacil-Ramos A.M., López-Maside A., Miralles-Espí M.T., et al. Prevención y vigilancia de la gripe en la Comunitat Valenciana. Temporada 2011-2012. Informe 135. Conselleria de Sanitat October 2012, Dirección General de Investigación y Salud Pública, Available: http://www.sp.san.gva.es/biblioteca/publicacion_dgsp.jsp?cod_pub_ran=709064217&tacc=15 [accessed 10.05.13].
15. Huckriede A., Bungener L., Stegmann T., Daemen T., Medema J., Palache A.M., et al. The virosome concept for influenza vaccines. Vaccine 2005, 23(Suppl. 1):S26-S38.
16. Martin-Moreno J.M., Alonso P., Claveria A., Gorgojo L., Peiró S. Spain: a decentralised health system in constant flux. Br Med J 2009, 338:b1170.
17. Puig-Barberà J., Arnedo-Pena A., Pardo-Serrano F., Tirado-Balaguer M.D., Pérez-Vilar S., Silvestre-Silvestre E., et al. Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case-control study. Vaccine 2010, 28:7460-7467.
18. González Morán F., Muñoz Criado I., Vanaclocha H. Grupo de trabajo del Análisis de Vigilancia Epidemiológica (AVE) de la Comunidad Valenciana. Gac Sanit 2008, 22:162-167.
19. Librero J., Ordiñana R., Peiró S. Automated analysis of the quality of the minimum set of basic data. Implications for risk-adjusting systems. Gac Sanit 1998, 12:9-21.
20. World Health Organization Recommended composition of influenza virus vaccines for use in the 2011-2012 northern hemisphere influenza season. Wkly Epidemiol Rec 2011, 86:86-90.
21. Puig-Barberà J., Díez-Domingo J., Arnedo-Pena A., Ruiz-García M., Pérez-Vilar S., Micó-Esparza J.L., et al. Effectiveness of the 2010-2011 seasonal influenza vaccine in preventing confirmed influenza hospitalizations in adults: a case-case comparison, case-control study. Vaccine 2012, 30:5714-5720.
22. Puig-Barberà J., Natividad-Sancho A., Calabuig-Pérez J., Lluch-Rodrigo J.A., Pastor-Villalba E., Martínez-Úbeda S., et al. MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system. Vaccine 2013, 31:3995-4002.
23. Ansaldi F., Orsi A., de Florentiis D., Parodi V., Rappazzo E., Coppelli M., et al. Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60: evaluation of immunogenicity, cross-protection, safety and tolerability. Hum Vaccine Immunother 2013, 9:591-598.
24. Van Damme P., Arnou R., Kafeja F., Fiquet A., Richard P., Thomas S., et al. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect Dis 2010, 10:134.
25. Holland D., Booy R., De Looze F., Eizenberg P., McDonald J., Karrasch J., et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008, 198:650-658.
26. Arnou R., Icardi G., De Decker M., Ambrozaitis A., Kazek M.P., Weber F., et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009, 27:7304-7312.
27. Valladeau J., Saeland S. Cutaneous dendritic cells. Semin Immunol 2005, 17:273-283.
28. Randolph G.J., Angeli V., Swartz M.A. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol 2005, 5:617-628.
29. Mangtani P., Cumberland P., Hodgson C.R., Roberts J.A., Cutts F.T., Hall A.J. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. J Infect Dis 2004, 190:1-10.
30. Delgado-Sanz C., Jiménez-Jorge S., López-Perea N., Pozo F., Gómez-Barroso D., Flores V., et al. Vigilancia de la gripe en España, Temporada 2011-12 (desde la semana 40/2011 hasta la semana 20/2012). Boletín Epidemiológico Semanal 2013, 20:153-167.
31. Castilla J., Martinez-Baz I., Martinez-Artola V., Reina G., Pozo F., Garcia Cenoz M., et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill 2013, 18. [pii: 20388].
32. Pebody R., Andrews N., McMenamin J., Durnall H., Ellis J., Thompson C., et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill 2013, 18. [pii: 20389].
33. Kissling E., Valenciano M., Larrauri A., Oroszi B., Cohen J., Nunes B., et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveill 2013, 18. [pii 20390].
34. Jiménez-Jorge S., de Mateo S., Delgado-Sanz C., Pozo F., Casas I., Garcia-Cenoz M., et al. Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination. BMC Infect Dis 2013, 13:441.
35. Skowronski D.M., Janjua N.Z., De Serres G., Sabaiduc S., Eshaghi A., Dickinson J.A., et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLOS ONE 2014, 9:e92153.
36. Skowronski D.M., Janjua N.Z., Sabaiduc S., De Serres G., Winter A.L., Gubbay J.B., et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-12 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis 2014, 210:126-137.